Jacobson I, McHutchison J, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.
Poordad F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.
Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329–37.PubMedCrossRef
Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509–16.PubMedCrossRef
McGowan CE, Monis A, Bacon BR, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013 Apr;57(4):1325–32.
Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013 Mar;207 Suppl 1:S19–25.
McGowan CE, FriedMW. Barriers to hepatitis C treatment. Liver Int. 2012 Feb;32 Suppl 1:151–6.
North CS, Hong BA, Adewuyi SA, et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry. 2013;35(2):122–8.
•• Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859–61. This report estimates the proportion of HCV infected persons in the United States who have been tested
, received care and completed anti
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.PubMedCrossRef
Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45–53.PubMedCrossRef
Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;16;368(20):1907–17.CrossRef
Martin NK, Vickerman P, Grebely J, et al.: HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013 [Epub ahead of print].
Durier N, Nguyen C, White LJ. Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One. 2012;7(4):e34548.PubMedCrossRef
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef
Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2362–8.PubMedCrossRef
Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.PubMedCrossRef
Chak E, Talal A, Sherman K, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31:1090–101.PubMedCrossRef
Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137(5):1680–6.PubMedCrossRef
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73.PubMedCrossRef
Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45(2):17–24.CrossRef
Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012 Feb 21;156(4):263–70.
Ly K, Xing J, Klevens M, et al. The growing burden of mortality from viral hepatitis in the US, 1999–2007. Ann Intern Med. 2012;156(4):271.PubMedCrossRef
Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777–82.PubMedCrossRef
Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26(Suppl):62S–5.PubMedCrossRef
Smith BD, Patel N, Beckett GA, et al.: Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999–2008. [abstract] American Association for the Study of Liver Disease, San Francisco (CA)2011.
CDC: 2011 surveillance summary in press
CDC. Hepatitis C virus infection among adolescents and young adults –Massachusetts, 2002—2009. MMWR. 2011;60(17):537–54.
Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis. 2013;56(10):1480–7.PubMedCrossRef
CDC. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005–2010. MMWR. 2011;60(28):945–50.
Institute of Medicine. Committee for the Study of the Future of Public Health, Division of Health Care Services: The future of public health. Washington, DC: National Academy Press; 1988.
Tsui JI, Maselli J, Gonzales R. Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. Dig Dis Sci. 2009;54(12):2694–8.
CDC. Hepatocellular carcinoma - United States, 2001–2006. MMWR. 2010;7;59(17):517–20.
CDC. Testing for HCV infection: An Update of Guidance for Clinicians and Laboratorians. MMWR. 2013;62(18):362–5.
Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH. A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users. Hepatology. 2013;57(3):944–52.PubMedCrossRef
Macalino GE, Vlahov D, Dickinson BP, Schwartzapfel B, Rich JD. Community incidence of hepatitis B and C among reincarcerated women. Clin Infect Dis. 2005 Oct 1;41(7):998–1002.
•• U.S. Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis. Washington, DC: HHS; 2011. p. p. 1–76. Prompted by a 2010 IOM report on the state of viral hepatitis prevention in the United States, this report outlines a comprehensive approach to viral hepatitis prevention that includes strategies to improve HCV education, testing, care and treatment, surveillance, and delivery of services to populations at risk. Many action steps within this plan have been undertaken by CDC and other HHS agencies, and additional actions will soon be put forth in an updated 2014–2016 viral hepatitis action plan.
•• Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: The National Academies Press; 2010. In this report, IOM identified viral hepatitis as an “underappreciated health concern for the nation” and recommended ways for the federal government to improve prevention of HCV transmission and disease. This report raised awareness of the silent epidemic of viral hepatitis in the United States, outlining expectations for public health policy and spurring development of a U.S. viral hepatitis action plan.
•• CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR. 2012;61(No. RR-04)):1–18. This CDC report provides expanded recommendations for HCV testing based on evidence that persons born during 1945–1965 represent 81% of all persons living with HCV and three quarters of HCV-associated mortality. The U.S. Preventive Services Task Force has issued similar recommendations. These recommendations will facilitate implementation of both risk-based and birth-cohort-based strategies for HCV testing and linkage to care and treatment.
Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2013;56(1):40–50.PubMedCrossRef
CDC. Characteristics of persons with chronic hepatic tis B—San Francisco, California, 2006. MMWR. 2007;56(18):446–8.
Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011 Jun 9;364(23):2199–207.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.PubMedCrossRef
Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.PubMedCrossRef
Ruark A, Shelton JD, Halperin DT, et al. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet. 2009;373:1078.PubMedCrossRef
Wood E, Milloy MJ, Montaner JS. HIV treatment as prevention among injection drug users. Curr Opin HIV AIDS. 2012;7(2):151–6.PubMedCrossRef